3Schoenfeld P,Kimmey MB,Scheiman J,et al.Review article:nonsteroidal anti-inflammatory drug-associated gastrointestinal complications-guidelines for prevention and treatment.Aliment Pharmacol Ther,1999,13:1273-1285.
4Cullen D,Bardhan KD,Eisner M,et al.Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users.Aliment Pharmacol Ther,1998,12:135-140.
5Yeomans ND,Tulassay Z,Juhász L,et al.A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs.Acid Suppression Trial:Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.N Engl J Med,1998,338:719-726.
6Federman AD,Litke A,Morrison RS.Association of age with analgesic use for back and joint disorders in outpatient settings.Am J Geriatr Pharmacother,2006,4:306-315.
7Mizushima T.Strategy for development of NSAIDs with lower risk for side effects.Yakugaku Zasshi,2008,128:255-261.
8Insúa J,Mavros P,Hunsche E,et al.Exposure to nonsteroidal anti-inflammatory drugs among older adult patients hospitalized for peptic ulcer disease in Argentina:A case-control study.Am J Geriatr Pharmacother,2006,4:251-259.
9Laine L.GI risk and risk factors of NSAIDs.J Cardiovasc Pharmacol,2006,47 Suppl 1:S60-S66.
10Fialová P,Vlcek J.The role of anti-ulcerative drugs in treatment and prevention of gastropathies induced by nonsteroidal anti-inflammatory drugs.Vnitr Lek,2004,50:858-866.
